Lilly extends grip on U.S. rights to Cymbalta

(Reuters) - Eli Lilly & Co said on Friday that it gained six more months of U.S. exclusivity on its Cymbalta antidepressant for conducting pediatric studies, extending Lilly's hold on the $4 billi…
Read the full story: Reuters: Health News